pre-update Archives

Publication

Exposure-Response Analyses of Tremelimumab Monotherapy or in Combination with Durvalumab in Patients with Unresectable Hepatocellular Carcinoma

An novel single dose regimen of tremelimumab combined with durvalumab could be a way to…

Certara2023 年 1 月 26 日

Blog

简化非房室药代动力学分析的技巧和窍门

These Phoenix tips and tricks will help you exclude Lambda Z, name partial areas, and…

Certara2023 年 1 月 20 日

On-Demand Webinar

D360 as your organization’s extendable and central data engine

D360 is an industry-leading scientific data informatics platform providing a flexible, scalable, and customizable enterprise…

Certara2023 年 1 月 20 日

On-Demand Webinar

Physiologically-Based Pharmacokinetic Modeling & Simulation to Support Asciminib NDA Submission & Inform Drug Product Label

Physiologically based pharmacokinetic (PBPK) modeling and simulation has become an established approach to assess drug-drug…

Certara2023 年 1 月 13 日

Announcement

Certara Awarded NIH Contract for Toxicology Consulting Support

Certara toxicology experts to support NIH’s BPN and HEAL drug development programs for nervous system…

Certara2023 年 1 月 10 日

视频

如果您研发的药物是 CYP3A 底物，我们有好消息要告诉您！

Certara2023 年 1 月 9 日

Announcement

Ghent University wins the 2021/22 Certara-Simcyp Grant and Partnership Scheme

PRINCETON, N.J., 2023 年 1 月 9 日 — Certara, Inc. （纳斯达克股票代码：CERT), a global leader in biosimulation,…

Certara2023 年 1 月 9 日

White Paper

Drug interactions with therapeutic proteins, regulatory expectations and modeling and simulation approaches

Certara2023 年 1 月 3 日

Blog

New FDA Requirement to Support Labeling on DDIs in the Pediatric Population

The effects of drug-drug interactions (DDIs) could differ in the pediatric population compared to adults.…

Certara2022 年 12 月 21 日

Blog

The Phoenix Workflow Shortcuts Every Pharmacokineticist Needs

Certara’s Phoenix™ Pharmacokinetic and Pharmacodynamic (PK/PD) Platform can revolutionize your pharmaceutical organization’s approach to PK/PD…

Certara2022 年 12 月 16 日

沪ICP备2022021526号

Powered by Translations.com GlobalLink Web Software

pre-update

Exposure-Response Analyses of Tremelimumab Monotherapy or in Combination with Durvalumab in Patients with Unresectable Hepatocellular Carcinoma

简化非房室药代动力学分析的技巧和窍门

D360 as your organization’s extendable and central data engine

Physiologically-Based Pharmacokinetic Modeling & Simulation to Support Asciminib NDA Submission & Inform Drug Product Label

Certara Awarded NIH Contract for Toxicology Consulting Support

如果您研发的药物是 CYP3A 底物，我们有好消息要告诉您！

Ghent University wins the 2021/22 Certara-Simcyp Grant and Partnership Scheme

Drug interactions with therapeutic proteins, regulatory expectations and modeling and simulation approaches

New FDA Requirement to Support Labeling on DDIs in the Pediatric Population

The Phoenix Workflow Shortcuts Every Pharmacokineticist Needs

订阅时事通讯

快捷链接

解决方案

联系我们